Cardiorenal-Glycemic Status
Use
According to the National Kidney Foundation, there are approximately 37 million adults in the U.S. who have chronic kidney disease (CKD), and about 90% are unaware of their condition. Diabetes is the leading cause of CKD in the United States. The significant impact of CKD on cardiovascular disease (CVD) risk has been increasingly recognized. Patients with CKD are far more likely to die, predominantly from CVD, than to progress to end-stage renal disease (ESRD). Currently, mainstays of treatment for diabetic kidney disease include control of hypertension, hyperglycemia and dyslipidemia. This panel has been established to aid in the identification and monitoring of hyperglycemia, dyslipidemia and CKD in patients with a history of diabetes and/or kidney disease.
Special Instructions
This panel does not require the patient to be fasting at the time of collection.
Limitations
There may be variability in test results due to patient conditions or specimen handling issues. The presence of hemolysis, lipemia, or an improperly collected specimen may affect the accuracy of the results. It is also important to note that the results should be interpreted in conjunction with the patient's medical history, clinical symptoms, and other laboratory findings.
Methodology
Other
Biomarkers
LOINC Codes
- 4548-4
- 2160-0
- 8251-1
- 2161-8
- 14957-5
- 9318-7
- 2093-3
- 2571-8
- 2085-9
- 13458-5
- 13457-7
- 43396-1
- 98979-8
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
1 mL
Minimum Volume
Not provided
Container
Urine bottle